linjc16/ctgov huggingface dataset:
Tumor Growth Factors in Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells. By studying tumor growth factors in hepatocellular carcinoma, one may know the tumor behavior, its relationship with clinical manifestation or invasion, and could be used as diagnostic or prognostic tools.This study aims to study the relationship between tumor growth factors in HCC ant its clinical relevance.

Detailed Description
-----------------
The clinical relevance of patients will be evaluated by the concentrations of tumor growth factors.

Official Title
-----------------
Insulin-like Growth Factors (IGF) Axis (IGFs, Its Binding Proteins,Receptors), Transforming Growth Factor Alpha and Beta 1 and Epidermal Growth Factor in the Urine and Serum of Patients With Hepatocellular Carcinoma.

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Biological: tumor growth factor concentration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histology proven HCC Exclusion Criteria: No definitely diagnosed tumor
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br>Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls | |
| 1<br>Patients with hepatocellular carcinoma and Healthy controls | Biological: tumor growth factor concentration<br>* spot urine or blood collection will be used to measure specific tumor growth factor<br>* Other names: serum concentration of tumor growth factor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| distant metastasis |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tumor growth factor
Axium Coil in Completing Endovascular Aneurysm Surgery Study

Study Overview
=================
Brief Summary
-----------------
The current observational evaluation is designed to evaluate the performance of the Axium™ MicroFx™ Detachable Coil System for the treatment of intracranial aneurysms in the real life practice.

Detailed Description
-----------------
Up to 25 patients from from US centers are anticipated to be enrolled for this evaluation. Published literature on coils with electrolytic, thermal or hydraulic detachment will serve as the basis for control comparisons to the Axium™ MicroFx™ Detachable Coil System for patients undergoing embolization of intracranial aneurysm. Comparison will be based on criteria evaluating the safety of the procedure, the reliability of detachment, the occlusion stability and the packing density impact.

Official Title
-----------------
Axium Coil in Completing Endovascular Aneurysm Surgery Study: A Single-center, Prospective Observational Registry

Conditions
-----------------
Intracranial Aneurysm

Intervention / Treatment
-----------------
* Device: MicroFx™ PGLA COILS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of one or more intracranial aneurysm, either ruptured or unruptured. Information on data collection provided to the patient or legally authorized representative and signed informed consent. Aneurysm diameter ≤10mm Age range of 18 - 90. Exclusion Criteria: Aneurysm previously treated. Aneurysm AVM related or dissecting. Participation in a clinical investigation of other aneurysm treating or related devices. Any condition that would preclude the conduct of protocol follow-up. Aneurysm anatomy that is determined inappropriate for Axium coil placement, prior to opening of an Axium coil.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MicroFx™ PGLA Treated Subjects<br> | Device: MicroFx™ PGLA COILS<br>* . This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients presenting with an intracranial aneurysm
Strategies to Optimize Positive End-expiratory Pressure (PEEP) in Patients With Acute Lung Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this study in patients suffering from acute lung injury is to determine whether positive end-expiratory pressure (PEEP) setting guided by electrical impedance tomography (EIT) influences pulmonary gas exchange, lung mechanics, ventilation/perfusion matching and homogeneity of regional ventilation when compared to other PEEP setting strategies such as the open lung concept or the ARDSnet protocol.

Official Title
-----------------
Influence of Different Strategies to Optimize Positive End-expiratory Pressure on Pulmonary Gas Exchange, Perfusion/Ventilation Matching and Homogeneity of Ventilation in Patients With Acute Lung Injury

Conditions
-----------------
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure

Intervention / Treatment
-----------------
* Procedure: PEEP titration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute lung injury, need for optimization of ventilatory settings Exclusion Criteria: preexisting chronical lung disease, pneumothorax, pace maker, hemodynamical instability, increased intracranial pressure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acute Lung Injury / ARDS<br>Patient under mechanical suffering from ALI or ARDS | Procedure: PEEP titration<br>* PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT<br>* Other names: electrical impedance tomography guided setting of PEEP;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| homogeneity of regional ventilation delay | influence of different PEEP titration strategies on homogeneity of regional ventilation delay measured by electrical impedance tomography | up to eight hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary gas exchange, lung mechanics and ventilation/perfusion matching | influence of different PEEP titration strategies on pulmonary gas exchange, lung mechanics and ventilation/perfusion matching | up to eight hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
electrical impedance tomography, positive end-expiratory pressure, regional ventilation delay index
Simple Verbal Intervention for Adequately Collecting Sputum

Study Overview
=================
Brief Summary
-----------------
simple verbal intervention with figure of lung and upper respiratory tract will be helpful to adequately collecting sputum. and in the acceptable specimen based on Gram stain, positivity for AFB stain and culture rate will be higher.

Detailed Description
-----------------
suspicious patients for pulmonary tuberculosis are randomized to control or education group. patients in education group will be educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.

Official Title
-----------------
The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing

Conditions
-----------------
Suspicious for Pulmonary Tuberculosis

Intervention / Treatment
-----------------
* Behavioral: education by brochure
* Behavioral: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years 2009.7 2010.7 patients with suspicious pulmonary tuberculosis who visited Boramae Hospital Exclusion Criteria: on medication for tuberculosis patients who medicated with fluoroquinolone within 1month patients without consciousness or patients who cannot expectorate sputum hemoptysis over 50cc per day patients who don't consent on the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: education<br>educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum. | Behavioral: education by brochure<br>* educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.<br>|
| Placebo Comparator: control<br>patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure. | Behavioral: control<br>* patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| culture result of Mycobacteria in sputum |  | 8wk after AFB culture | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acceptable sputum, AFB culture, pulmonary tuberculosis
Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis

Study Overview
=================
Brief Summary
-----------------
Hyperbilirubinemia is reported to be a positive predictor in diagnosing perforated appendicitis. Therefore we analysed the diagnostic accuracy of serum bilirubin in discriminating between perforated and simple/no appendicitis. Methods: All consecutive patients undergoing appendectomy for suspected appendicitis from May 2009 to August 2011 were analysed. Primary endpoint was the diagnostic accuracy of serum bilirubin levels to detect perforated appendicitis.

Official Title
-----------------
Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis

Conditions
-----------------
Appendicitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients undergoing appendectomy for suspected appendicitis Exclusion Criteria: preexisting liver disease

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy of serum bilirubin | assessment of the diagnostic accuracy of hyperbilirubinemia (defined as serum bilirubin above 1.1 md/dl) | 24h within initial presentation with clinical symptoms |
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate efficacy of gemcitabine and cisplatin combined with either radical cystectomy or radiotherapy in the treatment of bladder cancer.

Official Title
-----------------
The Evaluation of Efficacy and Toxicity of Combined Treatment: Neoadjuvant Chemotherapy (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer Stage T2b-T3 NO/Nx M0

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Drug: gemcitabine
* Drug: cisplatin
* Procedure: radical cystectomy
* Procedure: radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically or cytologically proven urothelial carcinoma of the urinary bladder in stage T2b-T3, N0/Nx, M0. Patients must have measurable disease. Response assessment will be evaluated according to RECIST criteria. Measurable lesions with clearly defined margins will be evaluated by X-Ray, Transvesical Ultrasound, CT-Scan or MRI, cystoscopy. Lesions serving as measurable disease must have the longest diameter of greater than or equal to 20 mm as measured with conventional techniques or greater than or equal 10 mm with spiral CT scan. Lesions measured by physical examination must have a longest diameter of greater than or equal 20 mm. Exclusion Criteria: Patients with prior or concomitant malignant diseases (other than appropriately treated basal cell carcinoma of the skin or carcinoma of the cervix) PSA greater than 5.0 ng/mL Concurrent administration of any other tumor therapy, including radiotherapy, cytotoxic chemotherapy, immunotherapy, molecular target therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: gemcitabine|nan|
|Drug: cisplatin|nan|
|Procedure: radical cystectomy|nan|
|Procedure: radiotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate efficacy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate pathological complete responses |  |  | 
| To evaluate progression free survival |  |  | 
| To evaluate overall survival |  |  | 
| To evaluate time to disease progression |  |  | 
| To evaluate safety |  |  |
Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to detect new urinary biomarkers that can be used as predictors on renal function in congenital hydronephrosis caused by unilateral ureteral obstruction (UUO) and to elucidate the pathophysiology of UUO.

Official Title
-----------------
Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis

Conditions
-----------------
Ureteral Obstruction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children referred to surgical treatment of congenital hydronephrosis caused by ureteral obstruction. Declining function of the hydronephrotic kidney more than 5 %, and to less than 40 % of the total renal function OR ipsilateral flank pain. Exclusion Criteria: Bilateral hydronephrosis Previous operation in the urinary system except operation for phimosis and other deformations of the external genital organs. Deformations in the lower part of the ureter, bladder and urethra. Urinary stones. Reflux. Urinary tract infections < 6 months. Neurogenic bladder dysfunction. GFR < 40 % standardized to age. Non-compliance. Linguistic difficulties.

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Children referred to surgical treatment of congenital hydronephrosis | |
| 2<br>15 age- and sex-matched controls | |
| Children with healthy pelvic tissue<br>Children referred to nephrectomy due to nephrotic syndrome | |
| Adults with healthy pelvic tissue<br>Adults referred to nephrectomy due to another cause than hydronephrosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary cytokines |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hydronephrosis, Ureteral obstruction
Efficacy of S-Adenosylmethionine in Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
Fundamentally, the trial aims to conduct a gold-standard test of the clinical impact of SAM-e in the treatment of depressed mood and general symptoms of fibromyalgia (FMS). As such, salient clinical and pathological parameters will be assessed over an 8-week period in 60 patients who will be provided with either SAM-e or a placebo preparation . On the basis of previous literature, it is hypothesised that patients in the active treatment group will experience moderate but significant improvements across the clinical measures, and that these gains will be significantly greater than any reported in the placebo group. All patients will provide informed consent. All procedures will be conducted under medical supervision and the preparation itself is very safe when used in the manner proposed for the trial

Official Title
-----------------
Double-Blind, Placebo-Controlled Trial of the Impact of S-Adenosyl-L-Methionine (SAM-e) on the Mood and Other Symptoms in Fibromyalgia

Conditions
-----------------
Fibromyalgia Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: SAM-e (S-Adenosyl-L-Methionine)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Fibromyalgia by a medical practitioner Exclusion Criteria: Pregnancy, Manic and hypomanic conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: P<br>Placebo Control Group | Dietary Supplement: SAM-e (S-Adenosyl-L-Methionine)<br>* One 400 mg tablet daily in the morning.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom reduction in Fibromyalgia. Specifically we expect a reduction in depressive symptoms, sleep disturbances and gastric disturbances. |  | Measured at three points in time: pre-trial and at 4 and 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examination of dose-response data and the nature of the placebo effect in these conditions. |  | Measured at three points in time: pre-trial and at 4 and 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
S-Adenosylmethionine
Single Complete Compression Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy and Postpartum

Study Overview
=================
Brief Summary
-----------------
The objective of the EDVIGE study is to determine whether a negative single distal and proximal leg veins compression ultrasonography safely rules out the diagnosis of deep vein thrombosis in pregnant and post-partum women with clinical suspicion of DVT.

Detailed Description
-----------------
A single distal and proximal leg veins compression ultrasonography has been shown to safely rule out the diagnosis of DVT when negative. The safety of this strategy has never been verified in pregnant or postpartum women. It could however be limited in that clinical setting, because of modified hemodynamics, hampered observation conditions, lack of respiratory modulation, higher proportion of isolated iliac deep vein thromboses. The objective of the EDVIGE study is to assess the safety of this diagnostic strategy during pregnancy and post-partum.

Official Title
-----------------
Diagnostic Exclusion Value of a Negative Single Distal and Proximal Lower Limb Veins Compression Ultrasonography in Pregnant and Post-partum Women With a Clinically Suspected Deep Vein Thrombosis

Conditions
-----------------
Deep Vein Thrombosis

Intervention / Treatment
-----------------
* Other: Lower limb veins compression ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with an ongoing pregnancy or within three-months post-partum and a clinically suspected deep vein thrombosis Exclusion Criteria: suspicion of pulmonary embolism age less than 18 years impossible follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography | Other: Lower limb veins compression ultrasonography<br>* Distal and proximal lower limb veins compression ultrasonography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objectively confirmed thromboembolic events |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, postpartum, deep vein thrombosis, venous thromboembolism, diagnosis, compression ultrasonography